Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.4009
Abstract: 4009 Background: Survival outcomes are historically poor in patients (pts) with advanced/metastatic iCCA, with median overall survival (mOS) times of approximately 1 year with first-line gemcitabine plus cisplatin and approximately 6 months with second-line chemotherapy.…
read more here.
Keywords:
safety;
icca harboring;
icca;
analysis ... See more keywords